Presentations made painless

Company > Akero Therapeutics Inc: Business Model, SWOT Analysis, and Competitors 2023

Akero Therapeutics Inc: Business Model, SWOT Analysis, and Competitors 2023

Published: Apr 21, 2023

Inside This Article


    Akero Therapeutics Inc is a renowned biotechnology company that focuses on developing innovative treatments for serious metabolic diseases. This blog article will delve into their business model, SWOT analysis, and a comprehensive examination of their competitors in 2023. By analyzing Akero Therapeutics' strengths, weaknesses, opportunities, and threats, readers will gain valuable insights into the company's strategic positioning in the highly competitive biotech industry. Additionally, understanding the landscape of their competitors will provide a broader perspective on Akero Therapeutics' growth potential and future prospects.

    What You Will Learn:

    • Who owns Akero Therapeutics Inc and the significance of their ownership in the company's operations and decision-making.
    • The mission statement of Akero Therapeutics Inc and how it guides the company's overall goals and strategies.
    • The various revenue streams and business strategies employed by Akero Therapeutics Inc to generate income.
    • A comprehensive explanation of Akero Therapeutics Inc's Business Model Canvas, detailing the key elements that contribute to the company's success.
    • A list of the main competitors of Akero Therapeutics Inc and an understanding of how they impact the company's market position and growth prospects.
    • An in-depth SWOT analysis of Akero Therapeutics Inc, evaluating its strengths, weaknesses, opportunities, and threats in the industry.

    Who owns Akero Therapeutics Inc?


    Akero Therapeutics Inc. is a biotechnology company focused on developing innovative treatments for metabolic diseases. As with any company, understanding the ownership structure of Akero Therapeutics Inc. is crucial for investors, stakeholders, and potential partners. In this section, we will delve into the ownership of Akero Therapeutics Inc., including its major shareholders and institutional investors.

    Major Shareholders

    Dr. Alexander Kamb

    Dr. Alexander Kamb, one of the founders of Akero Therapeutics Inc., is a prominent figure in the biotech industry. As of the latest available information, Dr. Kamb holds a significant stake in the company. With his extensive experience in drug discovery and development, his ownership signifies a strong commitment to the success of Akero Therapeutics Inc.

    Venrock Healthcare Capital Partners

    Venrock, a venture capital firm specializing in healthcare investments, is another major shareholder of Akero Therapeutics Inc. They have a proven track record of supporting early-stage biotech companies and have made significant investments in Akero Therapeutics Inc. Their involvement highlights the potential they see in the company's therapeutic approach and its market prospects.

    Institutional Investors

    Akero Therapeutics Inc. has attracted interest from several well-known institutional investors. These investors are renowned for their expertise in the healthcare and biotechnology sectors, and their involvement indicates confidence in the company's future prospects. Some notable institutional investors in Akero Therapeutics Inc. include:

    Fidelity Management & Research Company LLC

    Fidelity Management & Research Company is a well-established investment management firm known for its extensive healthcare portfolio. They have invested in numerous biotech companies, including Akero Therapeutics Inc., which demonstrates their belief in the company's potential for success.

    BlackRock Inc.

    BlackRock Inc., a leading global investment management corporation, has also shown interest in Akero Therapeutics Inc. Their involvement signifies the company's appeal to institutional investors seeking growth opportunities in the healthcare sector. BlackRock's investment further strengthens Akero Therapeutics Inc.'s financial and strategic position.

    The Vanguard Group

    The Vanguard Group, a renowned investment management company, has made investments in Akero Therapeutics Inc. Their involvement highlights the company's attractiveness to long-term investors seeking exposure to promising biotech ventures. The Vanguard Group's support contributes to the overall stability and growth potential of Akero Therapeutics Inc.


    The ownership structure of Akero Therapeutics Inc. reveals a combination of significant individual shareholders and institutional investors who believe in the company's mission and potential. With Dr. Alexander Kamb's involvement as a major shareholder, along with the support of venture capital firm Venrock and reputable institutional investors like Fidelity Management & Research Company, BlackRock Inc., and The Vanguard Group, Akero Therapeutics Inc. has a strong foundation for success in the biotechnology industry.

    What is the mission statement of Akero Therapeutics Inc?

    The Mission Statement of Akero Therapeutics Inc

    Akero Therapeutics Inc is a biotechnology company that is dedicated to transforming the lives of patients with serious metabolic diseases. The company's mission statement reflects their commitment to improving the health and well-being of individuals affected by these conditions.

    At the core of Akero's mission is the goal to develop innovative, effective, and safe therapies that address the underlying causes of metabolic diseases. By focusing on the root causes rather than just managing symptoms, Akero aims to provide long-lasting solutions that can significantly enhance patients' quality of life.

    Akero Therapeutics Inc is driven by a patient-centric approach, putting the needs and aspirations of patients at the heart of everything they do. Their mission statement emphasizes the importance of understanding the unique challenges faced by individuals with metabolic diseases and tailoring their research and development efforts to meet those needs.

    In addition to developing novel therapies, Akero is committed to collaborating with healthcare providers, researchers, and patient advocacy groups to accelerate the translation of scientific discoveries into meaningful treatments. By fostering partnerships and working collaboratively, Akero aims to leverage collective expertise and resources, ultimately advancing the understanding and treatment of metabolic diseases.

    Furthermore, Akero Therapeutics Inc recognizes the importance of ethics and integrity in their pursuit of scientific and medical advancements. Their mission statement emphasizes the company's commitment to conducting research and business operations with the highest ethical standards, ensuring transparency, and prioritizing patient safety.

    In summary, the mission statement of Akero Therapeutics Inc can be summed up as follows: To develop innovative therapies that target the root causes of metabolic diseases, improve the lives of patients, collaborate with healthcare providers and researchers, and conduct business with integrity and ethics.

    How does Akero Therapeutics Inc make money?

    Revenue Streams

    Akero Therapeutics Inc generates its revenue through a combination of sources. The primary revenue stream for the company is the sale of its pharmaceutical products. Akero Therapeutics specializes in the development and commercialization of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases.

    The company's flagship product, AKR-001, is a potential breakthrough treatment for NASH. As the product progresses through clinical trials and gains regulatory approvals, Akero Therapeutics anticipates significant revenue growth from its sales. NASH is a rapidly growing market, with a high unmet medical need, making it an attractive opportunity for the company.

    Akero Therapeutics also generates revenue through partnerships and collaborations. The company has entered into various agreements with pharmaceutical companies, academic institutions, and research organizations to further develop and commercialize its products. These collaborations not only provide additional funding but also give Akero Therapeutics access to resources and expertise that can expedite the development process.

    Furthermore, the company may generate revenue through licensing agreements and royalties. Akero Therapeutics holds a robust intellectual property portfolio comprising patents, trademarks, and trade secrets. By licensing its technology and intellectual property to other companies, Akero Therapeutics can earn royalties on the sales of products developed using its licensed technology.

    Future Growth Opportunities

    While Akero Therapeutics' current revenue streams primarily stem from the sale of its flagship product and collaborations, the company is strategically positioning itself for future growth. The company is actively investing in research and development to expand its product pipeline beyond NASH, targeting additional metabolic diseases.

    Akero Therapeutics aims to leverage its expertise in metabolic diseases to develop innovative therapies that address unmet medical needs. By diversifying its product portfolio, the company aims to capture a larger market share and generate additional revenue from the sale of these products.

    Additionally, Akero Therapeutics seeks to expand its global presence. The company is exploring opportunities to enter new markets and establish partnerships with international pharmaceutical companies. By expanding its reach beyond the domestic market, Akero Therapeutics can tap into new revenue streams and gain exposure to a wider patient population.

    In summary, Akero Therapeutics Inc generates revenue primarily through the sale of its pharmaceutical products, with its flagship product AKR-001 playing a central role. The company also benefits from collaborations, licensing agreements, and royalties, which contribute to its overall revenue stream. Looking ahead, Akero Therapeutics is focused on expanding its product pipeline, targeting new therapeutic areas, and exploring international markets to drive future growth.

    Akero Therapeutics Inc Business Model Canvas Explained

    What is the Business Model Canvas?

    The Business Model Canvas is a strategic management tool that helps organizations visualize and describe their business model in a concise and structured format. It provides a framework for understanding how a company creates, delivers, and captures value. Developed by Alexander Osterwalder and Yves Pigneur, the Business Model Canvas consists of nine key building blocks that explain the logic behind a company's operations and how it generates revenue.

    Akero Therapeutics Inc Business Model Canvas

    Akero Therapeutics Inc is a biotechnology company that focuses on the development of transformative treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. Let's explore how Akero's business model is structured using the Business Model Canvas:

    Customer Segments

    Akero Therapeutics Inc primarily targets pharmaceutical companies, healthcare providers, and patients suffering from NASH and related metabolic diseases. By understanding the specific needs and pain points of these customer segments, Akero can tailor its products and services accordingly.

    Value Proposition

    The value proposition of Akero Therapeutics Inc lies in its innovative and effective treatments for NASH. The company aims to provide therapeutic solutions that not only address the symptoms but also target the underlying causes of the disease. By offering breakthrough therapies, Akero aims to improve patients' quality of life and reduce the burden of NASH on healthcare providers.


    Akero Therapeutics Inc utilizes a multi-channel approach to reach its customers. This includes partnerships with pharmaceutical companies for distribution, collaborations with healthcare providers for clinical trials and patient access, as well as direct marketing and educational campaigns to raise awareness about NASH and its potential treatments.

    Customer Relationships

    Akero strives to build long-term relationships with its customers by providing ongoing support and engagement. This includes regular communication and updates on the progress of clinical trials, educational resources for healthcare providers, and patient support programs to ensure optimal treatment outcomes.

    Revenue Streams

    Akero Therapeutics Inc generates revenue through various sources. This includes licensing agreements with pharmaceutical companies for the commercialization of its therapies, sales of proprietary drugs, and potential partnerships or collaborations for research and development activities.

    Key Activities

    The key activities of Akero Therapeutics Inc revolve around research and development (R&D) efforts to discover and develop novel therapies for NASH and related metabolic diseases. This includes pre-clinical and clinical trials, regulatory compliance, intellectual property management, and strategic partnerships for additional expertise and resources.

    Key Resources

    The key resources for Akero include its team of research scientists, medical professionals, and experts in the field of NASH and metabolic diseases. Additionally, the company relies on its intellectual property, patents, laboratory facilities, and partnerships with academic institutions and pharmaceutical companies for access to specialized knowledge and resources.

    Key Partnerships

    Akero Therapeutics Inc understands the importance of strategic partnerships to accelerate its research and development efforts. The company collaborates with academic institutions, pharmaceutical companies, and regulatory bodies to access funding, expertise, and necessary approvals. These partnerships help Akero advance its therapies and bring them to market more efficiently.

    Cost Structure

    The cost structure of Akero Therapeutics Inc includes expenses related to research and development, clinical trials, manufacturing and production, marketing and sales, as well as general administrative costs. These investments are necessary to drive innovation, ensure regulatory compliance, and commercialize the company's therapies effectively.

    In conclusion, Akero Therapeutics Inc's business model canvas provides a comprehensive overview of how the company creates, delivers, and captures value in the field of NASH and metabolic diseases. By focusing on customer needs, innovative therapies, strategic partnerships, and efficient operations, Akero aims to make a meaningful impact in the healthcare industry.

    Which companies are the competitors of Akero Therapeutics Inc?

    Competitors of Akero Therapeutics Inc

    As a biotechnology company focused on developing transformative treatments for serious metabolic diseases, Akero Therapeutics Inc faces competition from several other players in the industry. Here are some notable competitors:

    1. Madrigal Pharmaceuticals Inc

    Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that specializes in the development of novel small-molecule drugs for the treatment of cardiovascular and metabolic diseases. Like Akero Therapeutics Inc, Madrigal Pharmaceuticals Inc focuses on non-alcoholic steatohepatitis (NASH) and other related liver diseases. Their lead product candidate, Resmetirom, is currently in Phase 3 clinical trials, aiming to treat NASH and reduce liver fat.

    2. Intercept Pharmaceuticals Inc

    Intercept Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics to treat chronic liver diseases, including NASH. Intercept's leading product, Ocaliva, is FDA-approved for the treatment of primary biliary cholangitis (PBC) and is being evaluated for its potential use in NASH. Intercept Pharmaceuticals Inc poses a significant competition to Akero Therapeutics Inc in the NASH treatment market.

    3. Genfit SA

    Genfit SA is a biopharmaceutical company that is actively engaged in the development of therapeutic and diagnostic solutions for metabolic, inflammatory, and liver diseases. Their lead compound, Elafibranor, is currently in Phase 3 clinical trials for NASH treatment. Genfit SA's strong focus on liver diseases and its advanced clinical development stage make it a formidable competitor for Akero Therapeutics Inc.

    4. Gilead Sciences Inc

    Gilead Sciences Inc is a global biopharmaceutical company that has a diverse portfolio of products targeting various diseases, including liver diseases. Gilead's lead investigational product for NASH treatment is Selonsertib, which is currently in Phase 3 clinical trials. With its extensive resources and expertise, Gilead Sciences Inc presents a significant challenge to Akero Therapeutics Inc in the competitive landscape of NASH therapeutics.

    While Akero Therapeutics Inc faces competition from these companies and others within the biotech industry, it is important to note that the landscape is constantly evolving. Factors such as clinical trial results, regulatory approvals, and market dynamics can significantly impact the competitive positioning of these companies.

    Akero Therapeutics Inc SWOT Analysis


    • Strong intellectual property portfolio: Akero Therapeutics Inc has a robust patent portfolio that provides them with a competitive advantage in the biopharmaceutical industry. This allows them to protect their innovations and maintain exclusivity in the market.

    • Innovative and differentiated product pipeline: The company's product pipeline is focused on developing treatments for non-alcoholic steatohepatitis (NASH) and other metabolic disorders. Their lead product candidate, AKR-001, has shown promising results in clinical trials and has the potential to address a significant unmet medical need.

    • Experienced management team: Akero Therapeutics Inc is led by a team of seasoned industry professionals with extensive experience in drug development and commercialization. This expertise helps ensure strategic decision-making and efficient execution of the company's business plan.


    • Limited financial resources: As a relatively young biopharmaceutical company, Akero Therapeutics Inc may face challenges in accessing sufficient financial resources to support their research and development efforts. This could potentially slow down the progress of their product pipeline and hinder their ability to compete with larger, well-funded competitors.

    • Dependency on a single product candidate: The success of Akero Therapeutics Inc heavily relies on the clinical development and commercialization of their lead product candidate, AKR-001. If this candidate fails to meet regulatory requirements or encounters unexpected safety or efficacy issues, it could significantly impact the company's revenue generation and overall viability.


    • Growing market for NASH treatments: Non-alcoholic steatohepatitis (NASH) is a rapidly growing market, driven by the increasing prevalence of obesity and metabolic disorders. Akero Therapeutics Inc has an opportunity to capture a significant share of this market by successfully launching AKR-001, which has shown potential in treating NASH patients.

    • Strategic partnerships and collaborations: Akero Therapeutics Inc can explore partnerships and collaborations with pharmaceutical companies or research institutions to leverage their resources and expertise. Such partnerships can help accelerate the development of their product pipeline and expand their reach in the market.


    • Intense competition: The biopharmaceutical industry is highly competitive, with numerous companies vying for a share of the market. Akero Therapeutics Inc faces the risk of competition from both established players and emerging biotech companies working on similar therapeutic areas. This could impact their market penetration and pricing power.

    • Regulatory challenges: The regulatory landscape for drug development and commercialization is complex and subject to changes. Akero Therapeutics Inc may face regulatory hurdles or delays in obtaining necessary approvals for their product candidates, which could impact their timeline and market entry.

    • Economic and market uncertainties: The global economy and healthcare market are susceptible to fluctuations and uncertainties. Economic downturns, changes in healthcare policies, or shifts in market dynamics could pose risks to Akero Therapeutics Inc's financial performance and growth prospects.

    Key Takeaways

    • Akero Therapeutics Inc is owned by a diverse group of shareholders, including venture capital firms, institutional investors, and individuals.
    • The mission statement of Akero Therapeutics Inc is to develop innovative therapies that address unmet medical needs in the field of metabolic diseases, with a focus on non-alcoholic steatohepatitis (NASH).
    • Akero Therapeutics Inc generates revenue through partnerships, collaborations, and licensing agreements with pharmaceutical companies, as well as through grants and funding from government agencies and foundations.
    • The Business Model Canvas of Akero Therapeutics Inc outlines key elements such as customer segments, value proposition, channels, customer relationships, revenue streams, key activities, key resources, and key partnerships.
    • The main competitors of Akero Therapeutics Inc in the field of metabolic diseases and NASH include Intercept Pharmaceuticals Inc, Genfit SA, Madrigal Pharmaceuticals Inc, and Galectin Therapeutics Inc.
    • In terms of SWOT analysis, Akero Therapeutics Inc's strengths include its strong scientific expertise, innovative pipeline, and strategic partnerships. However, it faces challenges such as regulatory uncertainties and intense competition in the market.


    In conclusion, Akero Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The ownership of the company is held by a combination of venture capital firms, including Apple Tree Partners and Atlas Venture.

    Akero's mission is to improve the lives of patients suffering from metabolic diseases by providing effective and safe therapies. Their focus on NASH, a condition with limited treatment options, highlights their commitment to addressing unmet medical needs.

    As for their revenue generation, Akero primarily relies on partnerships and collaborations with pharmaceutical companies, licensing agreements, and grants from research organizations. This diverse approach allows them to leverage external resources while maintaining control over their research and development efforts.

    The Akero Therapeutics Inc Business Model Canvas provides a comprehensive overview of the company's key activities, resources, and value proposition. By analyzing each component, it becomes evident that Akero's approach is centered around research and development, clinical trials, and strategic partnerships to bring their innovative therapies to market.

    In terms of competition, Akero faces several companies within the biopharmaceutical industry that are also developing treatments for NASH and metabolic diseases. Notable competitors include Intercept Pharmaceuticals, Genfit SA, and Madrigal Pharmaceuticals. The competition in this space is fierce, but Akero's unique approach and promising pipeline position them well to stand out in the market.

    Finally, conducting a SWOT analysis of Akero Therapeutics Inc reveals their strengths in innovative drug development, a strong management team, and a focus on unmet medical needs. However, they also face challenges such as regulatory hurdles, intense competition, and the need for substantial investment in research and development.

    Overall, Akero Therapeutics Inc is an exciting company with a clear mission and a promising future. Through their innovative approach and strategic partnerships, they are well-positioned to make a significant impact in the field of metabolic diseases, ultimately improving the lives of patients worldwide.


    What is the SWOT analysis according to Albert Humphrey?

    The SWOT analysis according to Albert Humphrey is a strategic planning tool that evaluates the strengths, weaknesses, opportunities, and threats of a business or organization. Albert Humphrey developed this model in the 1960s at the Stanford Research Institute and it has since become widely used in the business world. The analysis involves assessing the internal factors (strengths and weaknesses) that the organization has control over, as well as the external factors (opportunities and threats) that may impact its performance. The SWOT analysis helps organizations identify their competitive advantages, areas for improvement, potential growth opportunities, and potential risks or challenges.

    What are the opportunities in a SWOT analysis?

    Opportunities in a SWOT analysis refer to the external factors or situations that have the potential to benefit an organization or individual. These opportunities can be leveraged to achieve business goals or personal growth. Some common examples of opportunities in a SWOT analysis include:

    1. Market growth: Identifying emerging or untapped markets that can be targeted to expand the customer base and increase sales.

    2. Technological advancements: Embracing new technologies to improve operational efficiency, develop innovative products or services, or gain a competitive edge.

    3. Changing consumer trends: Adapting to evolving consumer preferences and behaviors to meet their needs and create new revenue streams.

    4. Strategic partnerships: Collaborating with other organizations to leverage their expertise, resources, or network to achieve mutually beneficial objectives.

    5. Economic factors: Utilizing favorable economic conditions, such as low interest rates or increased consumer spending, to drive business growth.

    6. Globalization: Expanding into international markets to access a larger customer base, reduce costs, or diversify revenue sources.

    7. Legislative or regulatory changes: Capitalizing on new policies or regulations that create opportunities for business expansion or differentiation.

    8. Talent acquisition: Attracting and retaining skilled employees who can contribute to innovation, productivity, or customer satisfaction.

    9. Competitive market gaps: Identifying gaps or weaknesses in competitors' offerings and developing products or services to fill those gaps.

    10. Social and environmental trends: Responding to growing consumer demands for sustainable and socially responsible products or services.

    By recognizing and seizing these opportunities, organizations can enhance their competitive position, achieve growth, and create value.

    Who are akero therapeutics competitors?

    Some of the competitors in the field of therapeutics that Akero Therapeutics may have include:

    1. Madrigal Pharmaceuticals
    2. Intercept Pharmaceuticals
    3. Viking Therapeutics
    4. CymaBay Therapeutics
    5. Galmed Pharmaceuticals
    6. Genfit SA
    7. Conatus Pharmaceuticals
    8. Enanta Pharmaceuticals
    9. Gilead Sciences
    10. Novartis

    Please note that the competitive landscape can change over time as new companies emerge or existing companies evolve their offerings.

    Is Akero Therapeutics a good stock to buy?

    I'm sorry, but as an AI language model, I don't have real-time access to financial data or the ability to provide personalized investment advice. Evaluating whether a stock is a good investment is a complex task that requires considering various factors such as the company's financial health, market conditions, industry trends, and individual investment goals. It's always recommended to conduct thorough research, consult with a financial advisor, and consider your own risk tolerance before making any investment decisions.

    Want to create a presentation now?

    • instantly

      Instantly Create A Deck

      Let PitchGrade do this for me

    • smile

      Hassle Free

      We will create your text and designs for you. Sit back and relax while we do the work.

    Explore More Content